Entering text into the input field will update the search result below

OncoCyte reports better-than-expected results from lung cancer liquid biopsy test; shares up 56% after hours

Jul. 09, 2018 4:49 PM ETOncoCyte Corporation (OCX) StockBy: Douglas W. House, SA News Editor1 Comment
  • Thinly traded micro cap OncoCyte (NASDAQ:OCX) is up 56% after hours on average volume in response to its announcement that a study of its DetermaVu lung cancer test based on Next Gen Sequencing (NGS), an enhanced algorithm and incorporating new biomarkers showed a level of performance beyond expectations.
  • The company says the use of the NGS platform may enable decentralized operations beyond its CLIA lab and the development of a CE-Mark'd test kit that could be distributed in Europe.
  • It plans to further test the new biomarkers on a broader set of samples aimed at selecting the best biomarker panel and algorithm. It expects to complete the expanded R&D validation study by year-end and the clinical validation study in H1 2019.

Recommended For You

About OCX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
OCX--
OncoCyte Corporation